Search

Your search keyword '"Pollo, B."' showing total 481 results
Start Over Author "Pollo, B."
481 results on '"Pollo, B."'

53. The β- radio-guided surgery: Method to estimate the minimum injectable activity from ex-vivo test

Author

Russomando, A., primary, Schiariti, M., additional, Bocci, V., additional, Colandrea, M., additional, Collamati, F., additional, Cremonesi, M., additional, Ferrari, M.E., additional, Ferroli, P., additional, Ghielmetti, F., additional, Ghisini, R., additional, Grana, C.M., additional, Mancini Terracciano, C., additional, Marafini, M., additional, Mirabelli, R., additional, Morganti, S., additional, Papi, S., additional, Patanè, M., additional, Pedroli, G., additional, Pollo, B., additional, Solfaroli Camillocci, E., additional, Traini, G., additional, and Faccini, R., additional

Published
2019
Full Text
View/download PDF

56. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+T cell activation in the presence of adjuvant temozolomide

Author

Pellegatta, S, Eoli, M, Cuccarini, V, Anghileri, E, Pollo, B, Pessina, S, Frigerio, S, Servida, M, Cuppini, L, Antozzi, C, Cuzzubbo, S, Corbetta, C, Paterra, R, Acerbi, F, Ferroli, P, Dimeco, F, Fariselli, L, Parati, E, Bruzzone, M, Finocchiaro, G, Pellegatta, Serena, Eoli, Marica, Cuccarini, Valeria, Anghileri, Elena, Pollo, Bianca, Pessina, Sara, Frigerio, Simona, Servida, Maura, Cuppini, Lucia, Antozzi, Carlo, CUZZUBBO, STEFANIA, CORBETTA, CRISTINA, Paterra, Rosina, Acerbi, Francesco, Ferroli, Paolo, DiMeco, Francesco, Fariselli, Laura, Parati, Eugenio A., Bruzzone, Maria Grazia, Finocchiaro, Gaetano, Pellegatta, S, Eoli, M, Cuccarini, V, Anghileri, E, Pollo, B, Pessina, S, Frigerio, S, Servida, M, Cuppini, L, Antozzi, C, Cuzzubbo, S, Corbetta, C, Paterra, R, Acerbi, F, Ferroli, P, Dimeco, F, Fariselli, L, Parati, E, Bruzzone, M, Finocchiaro, G, Pellegatta, Serena, Eoli, Marica, Cuccarini, Valeria, Anghileri, Elena, Pollo, Bianca, Pessina, Sara, Frigerio, Simona, Servida, Maura, Cuppini, Lucia, Antozzi, Carlo, CUZZUBBO, STEFANIA, CORBETTA, CRISTINA, Paterra, Rosina, Acerbi, Francesco, Ferroli, Paolo, DiMeco, Francesco, Fariselli, Laura, Parati, Eugenio A., Bruzzone, Maria Grazia, and Finocchiaro, Gaetano

Abstract

In a two-stage phase II study, 24 patients with first diagnosis of glioblastoma (GBM) were treated with dendritic cell (DC) immunotherapy associated to standard radiochemotherapy with temozolomide (TMZ) followed by adjuvant TMZ. Three intradermal injections of mature DC loaded with autologous GBM lysate were administered before adjuvant TMZ, while 4 injections were performed during adjuvant TMZ. According to a two-stage Simon design, to proceed to the second stage progression-free survival (PFS) 12 months after surgery was expected in at least 8 cases enrolled in the first stage. Evidence of immune response and interaction with chemotherapy were investigated. After a median follow up of 17.4 months, 9 patients reached PFS12. In these patients (responders, 37.5%), DC vaccination induced a significant, persistent activation of NK cells, whose increased response was significantly associated with prolonged survival. CD8+T cells underwent rapid expansion and priming but, after the first administration of adjuvant TMZ, failed to generate a memory status. Resistance to TMZ was associated with robust expression of the multidrug resistance protein ABCC3 in NK but not CD8+T cells. The negative effect of TMZ on the formation of T cell-associated antitumor memory deserves consideration in future clinical trials including immunotherapy

Published
2018

61. Mutations targeting the coagulation pathway are enriched in brain metastases

Author

Richichi, C. (Cristina), Fornasari, L. (Lorenzo), Melloni, G.E.M. (Giorgio E. M.), Brescia, P. (Paola), Patanè, M. (Monica), Del Bene, M. (Massimiliano), Mustafa, D.A.M. (Dana), Kros, J.M. (Johan), Pollo, B. (Bianca), Pruneri, G. (Giancarlo), Sciandivasci, A. (Angela), Munzone, E. (Elisabetta), Dimeco, F. (Francesco), Pelicci, P.G. (Pier Giuseppe), Riva, L. (Laura), Pelicci, G. (Giuliana), Richichi, C. (Cristina), Fornasari, L. (Lorenzo), Melloni, G.E.M. (Giorgio E. M.), Brescia, P. (Paola), Patanè, M. (Monica), Del Bene, M. (Massimiliano), Mustafa, D.A.M. (Dana), Kros, J.M. (Johan), Pollo, B. (Bianca), Pruneri, G. (Giancarlo), Sciandivasci, A. (Angela), Munzone, E. (Elisabetta), Dimeco, F. (Francesco), Pelicci, P.G. (Pier Giuseppe), Riva, L. (Laura), and Pelicci, G. (Giuliana)

Abstract

Brain metastases (BMs) are the most common malignancy of the central nervous system. Recently it has been demonstrated that plasminogen activator inhibitor serpins promote brain metastatic colonization, suggesting that mutations in serpins or other members of the coagulation cascade can provide critical advantages during BM formation. We performed whole-exome sequencing on matched samples of breast cancer and BMs and found mutations in the coagulation pathway genes in 5 out of 10 BM samples. We then investigated the mutational status of 33 genes belonging to the coagulation cascade in a panel of 29 BMs and we identified 56 Single Nucleotide Variants (SNVs). The frequency of gene mutations of the pathway was significantly higher in BMs than in primary tumours, and SERPINI1 was the most frequently mutated gene in BMs. These findings provide direction in the development of new strategies for the treatment of BMs.

Published
2017
Full Text
View/download PDF

62. Mutations targeting the coagulation pathway are enriched in brain metastases

Author

Richichi, C, Fornasari, L, Melloni, GEM, Brescia, P, Patane, M, Del Bene, M, Mustafa, Dana, Kros, J.M., Pollo, B, Pruneri, G, Sciandivasci, A, Munzone, E, DiMeco, F, Pelicci, PG, Riva, L, Pelicci, G, Richichi, C, Fornasari, L, Melloni, GEM, Brescia, P, Patane, M, Del Bene, M, Mustafa, Dana, Kros, J.M., Pollo, B, Pruneri, G, Sciandivasci, A, Munzone, E, DiMeco, F, Pelicci, PG, Riva, L, and Pelicci, G

Published
2017

66. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution.

Author

Piccirillo, S. g., Combi, L., Cajola, L., Patrizi, A., Redaelli, S., Bentivegna, A., Baronchelli, S., Maira, Giulio, Pollo, B., Mangiola, Annunziato, Dimeco, F., Dalprà, L., Vescovi, A. l., Piccirillo , S.g., Combi , L., Cajola , L., Patrizi , A., Redaelli , S., Bentivegna , A., Baronchelli , S., Maira , Giulio, Pollo , B., Mangiola, Annunziato (ORCID:0000-0002-1378-4524), Dimeco , F., Dalprà , L., Vescovi , A.l., Piccirillo, S. g., Combi, L., Cajola, L., Patrizi, A., Redaelli, S., Bentivegna, A., Baronchelli, S., Maira, Giulio, Pollo, B., Mangiola, Annunziato, Dimeco, F., Dalprà, L., Vescovi, A. l., Piccirillo , S.g., Combi , L., Cajola , L., Patrizi , A., Redaelli , S., Bentivegna , A., Baronchelli , S., Maira , Giulio, Pollo , B., Mangiola, Annunziato (ORCID:0000-0002-1378-4524), Dimeco , F., Dalprà , L., and Vescovi , A.l.

Published
2009

67. Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma

Author

Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, Gandola, L., Massimino, M, Miceli, R, Giangaspero, F, Boschetti, L, Modena, P, Antonelli, M, Ferroli, P, Bertin, D, Pecori, E, Valentini, L, Biassoni, V, Garrè, M, Schiavello, E, Sardi, I, Cama, A, Viscardi, E, Scarzello, G, Scoccianti, S, Mascarin, M, Quaglietta, L, Cinalli, G, Diletto, B, Genitori, L, Peretta, P, Mussano, A, Buccoliero, A, Calareso, G, Barra, S, Mastronuzzi, A, Giussani, C, Marras, C, Balter, R, Bertolini, P, Giombelli, E, La Spina, M, Buttarelli, F, Pollo, B, Gandola, L, GIUSSANI, CARLO GIORGIO, and Gandola, L.

Abstract

Background This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). Methods WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. Results From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. Conclusions In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.

Published
2016

68. Expression of the neurogenic basic helix-loop-helix transcription factor NEUROG1 identifies a subgroup of medulloblastomas not expressing ATOH1

Author

Salsano, E, Croci, L, Giordana, Maria Teresa, Maderna, E, Lupo, L, Eoli, M, Pollo, B, Consalez, G, Finocchiaro, G., Salsano, E, Croci, L, Maderna, E, Lupo, L, Pollo, B, Giordana, Mt, Consalez, GIAN GIACOMO, and Finocchiaro, G.

Subjects
ATOH1, Cancer Research, Cerebellum, animal structures, Beta-catenin, Genes, myc, Nerve Tissue Proteins, Zinc Finger Protein GLI1, Mice, Basic Helix-Loop-Helix Transcription Factors, medicine, Animals, Humans, Cell Lineage, RNA, Messenger, Cerebellar Neoplasms, neoplasms, Transcription factor, In Situ Hybridization, beta Catenin, Otx Transcription Factors, Base Sequence, biology, Reverse Transcriptase Polymerase Chain Reaction, Wnt signaling pathway, Immunohistochemistry, nervous system diseases, Neuroepithelial cell, medicine.anatomical_structure, Oncology, Cerebellar cortex, Mutation, Basic and Translational Investigations, Cancer research, biology.protein, Neurology (clinical), Signal transduction, Medulloblastoma, Transcription Factors
Abstract

Medulloblastomas (MBs) are malignant tumors of the cerebellum. They commonly affect children, no more than 30% occurring in individuals older than 16 years, and are considered embryonic tumors since they originate from precursors present during cerebellar development. In particular, MBs may derive from cerebellar granule cell precursors (GCPs), which form a layer of proliferating committed cells in the subpial surface of the cerebellum during the fetal and the postnatal period. Neuroepithelial cells of the cerebellar ventricular zone (CVZ), displaced around the midline of the neuroectodermal tube, may constitute the other cells of origin of MBs.1 The idea that MBs have a double origin is molecularly supported by the expression of the neurotrophin receptor p75NTR,2 the calcium-binding protein calbin-din-D28k,3 and the human atonal homolog 1 (ATOH1) gene in distinct subsets of these tumors. ATOH1 is a basic helix-loop-helix (bHLH) transcription factor (TF), and its mouse homolog, Math1, is exclusively expressed in proliferating GCPs during cerebellar development. Math1 expression seems necessary to uncommitted precursors of the CVZ to differentiate first as GCPs and finally as postmitotic, cerebellar granule cells.4 ATOH1 is expressed only in a subgroup of MBs, suggesting that not all these tumors originate from the GCPs.5–7 Interestingly, MBs with ATOH1 transcript are commonly located in the hemispheres rather than in the vermis, as should be expected if they effectively originate from the GCPs.8 Since MBs expressing ATOH1 afflict almost exclusively adult patients, GCPs may be the cells of origin of adult MBs. On the other hand, there is no molecular marker, functionally analogous to ATOH1, identifying MBs deriving from precursor cells of the CVZ. Indeed, calbindin-D28k, which is considered a marker of MBs originating from the CVZ, is a calcium-binding protein, and it is also expressed in mature neurons. In contrast, neurogenin-1 (NEUROG1) is a proneural bHLH TF that functions as a determinant of neuronal identity and is expressed in a subset of interneuronal precursors of the murine spinal cord in a pattern complementary to Math1.9 Its role in cerebellar development, if any, was not yet investigated, but the expression of the human homolog, NEUROG1, was detected in a subset of human MBs and associated with a poor prognosis.10 Moreover, during development of the murine brain, Ngn1 is transiently expressed, and no transcript is detectable in adult nervous tissue, reinforcing its similarity to Math1.11 A distinct histogenesis may be associated with activation of different proliferative signaling pathways, as the SHH and WNT pathways. SHH is a glycoprotein secreted from Purkinje cells during development of the cerebellar cortex that interacts with the transmembrane PTCH receptor expressed by GCPs, stimulating their proliferation. PTCH mutations were found in sporadic MBs and in Gorlin syndrome, an autosomal-dominant cancer syndrome characterized by the propensity to develop multiple neoplasms, including basal cell carcinomas and MBs. The final common effector of the SHH-dependent signaling pathway is TF GLI1.12 In murine models, Gli1 plays an important role in the formation of MBs,13 even though its alteration does not appear to be a general requirement.14 On the other hand, the role of the SHH pathway in the development of neuroepithelial cells of the CVZ is unclear.15,16 Since MB cells conserve many characters of their cells of origin, it is likely that the SHH pathway does not play a relevant role in MBs originating from progenitors of the CVZ. The WNT pathway, on the contrary, may play a pivotal role in the pathogenesis of this latter subgroup. Dysregulation of the WNT-dependent signaling pathway has been involved in sporadic MBs and in Turcot syndrome, another autosomal-dominant cancer syndrome characterized by malignant tumors of the CNS associated with familial polyposis of the colon.17 Many WNT proteins and corresponding human frizzled-homolog receptors (FZDs) have been described, but much less is known about their role in the development of the human cerebellum. The WNT pathway is activated when WNT ligands bind to FZDs, causing stabilization of β-catenin and its translocation into the nucleus. In the nucleus, β-catenin activates transcription of a number of oncogenic targets, including MYC, although transcriptional activation by a β-catenin– independent pathway may be a mechanism for MYC overexpression in a subset of MBs.18 Here, we examined the mRNA expression of NEUROG1 in human MBs that were characterized for the expression of ATOH1, and the mRNA expression of Ngn1 in mouse embryonal cerebellum. In addition, we investigated the mRNA expression of GLI1 as marker of the SHH pathway activation, and nuclear β-catenin staining, β-catenin mutations, and/or mRNA expression of MYC as indicators of the WNT pathway activation. A link between the activation of these pathways and the mRNA expression of ATOH1 and NEUROG1 was assessed. Finally, in a smaller series of human MBs, we analyzed mRNA expression of OTX2, a TF that has been shown to be a further positive marker for MBs that originated from GCPs.19

Published
2007

71. First ex vivo validation of a radioguided surgery technique withβ-radiation.

Author

Solfaroli Camillocci, E., primary, Schiariti, M., additional, Bocci, V., additional, Carollo, A., additional, Chiodi, G., additional, Colandrea, M., additional, Collamati, F., additional, Cremonesi, M., additional, Donnarumma, R., additional, Ferrari, M.E., additional, Ferroli, P., additional, Ghielmetti, F., additional, Grana, C.M., additional, Mancini Terracciano, C., additional, Marafini, M., additional, Morganti, S., additional, Patanè, M., additional, Pedroli, G., additional, Pollo, B., additional, Recchia, L., additional, Russomando, A., additional, Toppi, M., additional, Traini, G., additional, and Faccini, R., additional

Published
2016
Full Text
View/download PDF

77. Pre-targeted immunodetection in glioma patients: tumor localization and single-photon emission tomography imaging of [99m TC] Pn AO-BIOTIN

Author

PAGANELLI G, MAGNANI P, ZITO F, LUCIGNANI G, SUDATI F, TRUCI G, MOTTA E, TERRENI M, POLLO B, GIOVANELLI M, CANAL N, SCOTTI G, KOCH P, MAECKE HR, FAZIO F., COMI , GIANCARLO, Paganelli, G, Magnani, P, Zito, F, Lucignani, G, Sudati, F, Truci, G, Motta, E, Terreni, M, Pollo, B, Giovanelli, M, Canal, N, Scotti, G, Comi, Giancarlo, Koch, P, Maecke, Hr, and Fazio, F.

Published
1994

88. P02.03 * INCREASED COUNTS OF NK AND NKT CELLS ARE ASSOCIATED WITH PROLONGED SURVIVAL IN PRIMARY GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL IMMUNOTHERAPY IN COMBINATION WITH RADIO- AND CHEMO-THERAPY

Author

Pellegatta, S., primary, Eoli, M., additional, Cantini, G., additional, Anghileri, E., additional, Antozzi, C., additional, Frigerio, S., additional, Bruzzone, M., additional, Pollo, B., additional, Parati, E., additional, and Finocchiaro, G., additional

Published
2014
Full Text
View/download PDF

92. Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010

Author

Nava, F., primary, Tramacere, I., additional, Fittipaldo, A., additional, Bruzzone, M. G., additional, DiMeco, F., additional, Fariselli, L., additional, Finocchiaro, G., additional, Pollo, B., additional, Salmaggi, A., additional, Silvani, A., additional, Farinotti, M., additional, and Filippini, G., additional

Published
2014
Full Text
View/download PDF

93. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution

Author

Piccirillo, S, Combi, R, Cajola, L, Patrizi, A, Redaelli, S, Bentivegna, A, Baronchelli, S, Maira, G, Pollo, B, Mangiola, A, Dimeco, F, Dalpra', L, Vescovi, A, Piccirillo, SGM, DiMeco, F, COMBI, ROMINA, REDAELLI, SERENA, BENTIVEGNA, ANGELA, DALPRA', LEDA, VESCOVI, ANGELO LUIGI, Piccirillo, S, Combi, R, Cajola, L, Patrizi, A, Redaelli, S, Bentivegna, A, Baronchelli, S, Maira, G, Pollo, B, Mangiola, A, Dimeco, F, Dalpra', L, Vescovi, A, Piccirillo, SGM, DiMeco, F, COMBI, ROMINA, REDAELLI, SERENA, BENTIVEGNA, ANGELA, DALPRA', LEDA, and VESCOVI, ANGELO LUIGI

Abstract

Glioblastomas (GBMs) contain transformed, self-maintaining, multipotent, tumour-initiating cancer stem cells, whose identification has radically changed our perspective on the physiology of these tumours. Currently, it is unknown whether multiple types of transformed precursors, which display alternative sets of the complement of properties of true cancer stem cells, can be found in a GBM. If different subsets of such cancer stem-like cells (CSCs) do exist, they might represent distinct cell targets, with a differential therapeutic importance, also depending on their characteristics and lineage relationship. Here, we report the presence of two types of CSCs within different regions of the same human GBM. Cytogenetic and molecular analysis shows that the two types of CSCs bear quite diverse tumorigenic potential and distinct genetic anomalies, and, yet, derive from common ancestor cells. This provides critical information to unravel the development of CSCs and the key molecular/genetic components underpinning tumorigenicity in human GBMs. © 2009 Macmillan Publishers Limited. All rights reserved.

Published
2009

94. Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma

Author

Filippini, G, Falcone, C, Boiardi, A, Broggi, G, Bruzzone, M, Caldiroli, D, Farina, R, Farinotti, M, Fariselli, L, Finocchiaro, G, Giombini, S, Pollo, B, Savoiardo, M, Solero, C, Valsecchi, M, Bruzzone, MG, Solero, CL, VALSECCHI, MARIA GRAZIA, Filippini, G, Falcone, C, Boiardi, A, Broggi, G, Bruzzone, M, Caldiroli, D, Farina, R, Farinotti, M, Fariselli, L, Finocchiaro, G, Giombini, S, Pollo, B, Savoiardo, M, Solero, C, Valsecchi, M, Bruzzone, MG, Solero, CL, and VALSECCHI, MARIA GRAZIA

Abstract

Reliable data on large cohorts of patients with glioblastoma are needed because such studies differ importantly from trials that have a strong bias toward the recruitment of younger patients with a higher performance status. We analyzed the outcome of 676 patients with histologically confirmed newly diagnosed glioblastoma who were treated consecutively at a single institution over a 7-year period (1997-2003) with follow-up to April 30, 2006. Survival probabilities were 57% at 1 year, 16% at 2 years, and 7% at 3 years. Progression-free survival was 15% at 1 year. Prolongation of survival was significantly associated with surgery in patients with a good performance status, whatever the patient's age, with an adjusted hazard ratio of 0.55 (p < 0.001) or a 45% relative decrease in the risk of death. Radiotherapy and chemotherapy improved survival, with adjusted hazard ratios of 0.61 (p = 0.001) and 0.89 (p = 0.04), respectively, regardless of age, performance status, or residual tumor volume. Recurrence occurred in 99% of patients throughout the follow-up. Reoperation was performed in one-fourth of these patients but was not effective, whether performed within 9 months (hazard ratio, 0.86; p = 0.256) or after 9 months (hazard ratio, 0.98; p = 0.860) of initial surgery, whereas second-line chemotherapy with procarbazine, lomustine, and vincristine (PCV) or with temozolomide improved survival (hazard ratio, 0.77; p = 0.008). Surgery followed by radiotherapy and chemotherapy should be considered in all patients with glioblastoma, and these treatments should not be withheld because of increasing age alone. The benefit of second surgery at recurrence is uncertain, and new trials are needed to assess its effectiveness. Chemotherapy with PCV or temozolomide seems to be a reasonable option at tumor recurrence.

Published
2008

95. OMICS AND PROGNSTIC MARKERS

Author

Adachi, K., primary, Sasaki, H., additional, Nagahisa, S., additional, Yoshida, K., additional, Hattori, N., additional, Nishiyama, Y., additional, Kawase, T., additional, Hasegawa, M., additional, Abe, M., additional, Hirose, Y., additional, Alentorn, A., additional, Marie, Y., additional, Poggioli, S., additional, Alshehhi, H., additional, Boisselier, B., additional, Carpentier, C., additional, Mokhtari, K., additional, Capelle, L., additional, Figarella-Branger, D., additional, Hoang-Xuan, K., additional, Sanson, M., additional, Delattre, J.-Y., additional, Idbaih, A., additional, Yust-Katz, S., additional, Anderson, M., additional, Olar, A., additional, Eterovic, A., additional, Ezzeddine, N., additional, Chen, K., additional, Zhao, H., additional, Fuller, G., additional, Aldape, K., additional, de Groot, J., additional, Andor, N., additional, Harness, J., additional, Lopez, S. G., additional, Fung, T. L., additional, Mewes, H. W., additional, Petritsch, C., additional, Arivazhagan, A., additional, Somasundaram, K., additional, Thennarasu, K., additional, Pandey, P., additional, Anandh, B., additional, Santosh, V., additional, Chandramouli, B., additional, Hegde, A., additional, Kondaiah, P., additional, Rao, M., additional, Bell, R., additional, Kang, R., additional, Hong, C., additional, Song, J., additional, Costello, J., additional, Nagarajan, R., additional, Zhang, B., additional, Diaz, A., additional, Wang, T., additional, Bie, L., additional, Li, Y., additional, Liu, H., additional, Luyo, W. F. C., additional, Carnero, M. H., additional, Iruegas, M. E. P., additional, Morell, A. R., additional, Figueiras, M. C., additional, Lopez, R. L., additional, Valverde, C. F., additional, Chan, A. K.-Y., additional, Pang, J. C.-S., additional, Chung, N. Y.-F., additional, Li, K. K.-W., additional, Poon, W. S., additional, Chan, D. T.-M., additional, Wang, Y., additional, Ng, H.-a. K., additional, Chaumeil, M., additional, Larson, P., additional, Yoshihara, H., additional, Vigneron, D., additional, Nelson, S., additional, Pieper, R., additional, Phillips, J., additional, Ronen, S., additional, Clark, V., additional, Omay, Z. E., additional, Serin, A., additional, Gunel, J., additional, Omay, B., additional, Grady, C., additional, Youngblood, M., additional, Bilguvar, K., additional, Baehring, J., additional, Piepmeier, J., additional, Gutin, P., additional, Vortmeyer, A., additional, Brennan, C., additional, Pamir, M. N., additional, Kilic, T., additional, Krischek, B., additional, Simon, M., additional, Yasuno, K., additional, Gunel, M., additional, Cohen, A. L., additional, Sato, M., additional, Aldape, K. D., additional, Mason, C., additional, Diefes, K., additional, Heathcock, L., additional, Abegglen, L., additional, Shrieve, D., additional, Couldwell, W., additional, Schiffman, J. D., additional, Colman, H., additional, D'Alessandris, Q. G., additional, Cenci, T., additional, Martini, M., additional, Ricci-Vitiani, L., additional, De Maria, R., additional, Larocca, L. M., additional, Pallini, R., additional, Theeler, B., additional, Lang, F., additional, Rao, G., additional, Gilbert, M., additional, Sulman, E., additional, Luthra, R., additional, Eterovic, K., additional, Routbort, M., additional, Verhaak, R., additional, Mills, G., additional, Mendelsohn, J., additional, Meric-Bernstam, F., additional, Yung, A., additional, MacArthur, K., additional, Hahn, S., additional, Kao, G., additional, Lustig, R., additional, Alonso-Basanta, M., additional, Chandrasekaran, S., additional, Wileyto, E. P., additional, Reyes, E., additional, Dorsey, J., additional, Fujii, K., additional, Kurozumi, K., additional, Ichikawa, T., additional, Onishi, M., additional, Ishida, J., additional, Shimazu, Y., additional, Kaur, B., additional, Chiocca, E. A., additional, Date, I., additional, Geisenberger, C., additional, Mock, A., additional, Warta, R., additional, Schwager, C., additional, Hartmann, C., additional, von Deimling, A., additional, Abdollahi, A., additional, Herold-Mende, C., additional, Gevaert, O., additional, Achrol, A., additional, Gholamin, S., additional, Mitra, S., additional, Westbroek, E., additional, Loya, J., additional, Mitchell, L., additional, Chang, S., additional, Steinberg, G., additional, Plevritis, S., additional, Cheshier, S., additional, Xu, J., additional, Napel, S., additional, Zaharchuk, G., additional, Harsh, G., additional, Gutman, D., additional, Holder, C., additional, Colen, R., additional, Dunn, W., additional, Jain, R., additional, Cooper, L., additional, Hwang, S., additional, Flanders, A., additional, Brat, D., additional, Hayes, J., additional, Droop, A., additional, Thygesen, H., additional, Boissinot, M., additional, Westhead, D., additional, Short, S., additional, Lawler, S., additional, Bady, P., additional, Kurscheid, S., additional, Delorenzi, M., additional, Hegi, M. E., additional, Crosby, C., additional, Faulkner, C., additional, Smye-Rumsby, T., additional, Kurian, K., additional, Williams, M., additional, Hopkins, K., additional, Palmer, A., additional, Williams, H., additional, Wragg, C., additional, Haynes, H. R., additional, Kurian, K. M., additional, White, P., additional, Oka, T., additional, Jalbert, L., additional, Elkhaled, A., additional, Jensen, R., additional, Salzman, K., additional, Schabel, M., additional, Gillespie, D., additional, Mumert, M., additional, Johnson, B., additional, Mazor, T., additional, Barnes, M., additional, Yamamoto, S., additional, Ueda, H., additional, Tatsuno, K., additional, Aihara, K., additional, Bollen, A., additional, Hirst, M., additional, Marra, M., additional, Mukasa, A., additional, Saito, N., additional, Aburatani, H., additional, Berger, M., additional, Taylor, B., additional, Popov, S., additional, Mackay, A., additional, Ingram, W., additional, Burford, A., additional, Jury, A., additional, Vinci, M., additional, Jones, C., additional, Jones, D. T. W., additional, Hovestadt, V., additional, Picelli, S., additional, Wang, W., additional, Northcott, P. A., additional, Kool, M., additional, Reifenberger, G., additional, Pietsch, T., additional, Sultan, M., additional, Lehrach, H., additional, Yaspo, M.-L., additional, Borkhardt, A., additional, Landgraf, P., additional, Eils, R., additional, Korshunov, A., additional, Zapatka, M., additional, Radlwimmer, B., additional, Pfister, S. M., additional, Lichter, P., additional, Joy, A., additional, Smirnov, I., additional, Reiser, M., additional, Shapiro, W., additional, Kim, S., additional, Feuerstein, B., additional, Jungk, C., additional, Friauf, S., additional, Unterberg, A., additional, Juratli, T. A., additional, McElroy, J., additional, Meng, W., additional, Huebner, A., additional, Geiger, K. D., additional, Krex, D., additional, Schackert, G., additional, Chakravarti, A., additional, Lautenschlaeger, T., additional, Kim, B. Y., additional, Jiang, W., additional, Beiko, J., additional, Prabhu, S., additional, DeMonte, F., additional, Sawaya, R., additional, Cahill, D., additional, McCutcheon, I., additional, Lau, C., additional, Wang, L., additional, Terashima, K., additional, Yamaguchi, S., additional, Burstein, M., additional, Sun, J., additional, Suzuki, T., additional, Nishikawa, R., additional, Nakamura, H., additional, Natsume, A., additional, Terasaka, S., additional, Ng, H.-K., additional, Muzny, D., additional, Gibbs, R., additional, Wheeler, D., additional, Zhang, X.-q., additional, Sun, S., additional, Lam, K.-f., additional, Kiang, K. M. Y., additional, Pu, J. K. S., additional, Ho, A. S. W., additional, Leung, G. K. K., additional, Loebel, F., additional, Curry, W. T., additional, Barker, F. G., additional, Lelic, N., additional, Chi, A. S., additional, Cahill, D. P., additional, Lu, D., additional, Yin, J., additional, Teo, C., additional, McDonald, K., additional, Madhankumar, A., additional, Weston, C., additional, Slagle-Webb, B., additional, Sheehan, J., additional, Patel, A., additional, Glantz, M., additional, Connor, J., additional, Maire, C., additional, Francis, J., additional, Zhang, C.-Z., additional, Jung, J., additional, Manzo, V., additional, Adalsteinsson, V., additional, Homer, H., additional, Blumenstiel, B., additional, Pedamallu, C. S., additional, Nickerson, E., additional, Ligon, A., additional, Love, C., additional, Meyerson, M., additional, Ligon, K., additional, Jalbert, L. E., additional, Nelson, S. J., additional, Bollen, A. W., additional, Smirnov, I. V., additional, Song, J. S., additional, Olshen, A. B., additional, Berger, M. S., additional, Chang, S. M., additional, Taylor, B. S., additional, Costello, J. F., additional, Mehta, S., additional, Armstrong, B., additional, Peng, S., additional, Bapat, A., additional, Berens, M., additional, Melendez, B., additional, Mollejo, M., additional, Mur, P., additional, Hernandez-Iglesias, T., additional, Fiano, C., additional, Ruiz, J., additional, Rey, J. A., additional, Stadler, V., additional, Schulte, A., additional, Lamszus, K., additional, Schichor, C., additional, Westphal, M., additional, Tonn, J.-C., additional, Morozova, O., additional, Katzman, S., additional, Grifford, M., additional, Salama, S., additional, Haussler, D., additional, Olshen, A., additional, Fouse, S., additional, Nakamizo, S., additional, Sasayama, T., additional, Tanaka, H., additional, Tanaka, K., additional, Mizukawa, K., additional, Yoshida, M., additional, Kohmura, E., additional, Northcott, P., additional, Jones, D., additional, Pfister, S., additional, Otani, R., additional, Takayanagi, S., additional, Saito, K., additional, Tanaka, S., additional, Shin, M., additional, Ozawa, T., additional, Riester, M., additional, Cheng, Y.-K., additional, Huse, J., additional, Helmy, K., additional, Charles, N., additional, Squatrito, M., additional, Michor, F., additional, Holland, E., additional, Perrech, M., additional, Dreher, L., additional, Rohn, G., additional, Goldbrunner, R., additional, Timmer, M., additional, Pollo, B., additional, Palumbo, V., additional, Calatozzolo, C., additional, Patane, M., additional, Nunziata, R., additional, Farinotti, M., additional, Silvani, A., additional, Lodrini, S., additional, Finocchiaro, G., additional, Lopez, E., additional, Rioscovian, A., additional, Ruiz, R., additional, Siordia, G., additional, de Leon, A. P., additional, Rostomily, C., additional, Rostomily, R., additional, Silbergeld, D., additional, Kolstoe, D., additional, Chamberlain, M., additional, Silber, J., additional, Roth, P., additional, Keller, A., additional, Hoheisel, J., additional, Codo, P., additional, Bauer, A., additional, Backes, C., additional, Leidinger, P., additional, Meese, E., additional, Thiel, E., additional, Korfel, A., additional, Weller, M., additional, Nagae, G., additional, Nagane, M., additional, Sanborn, J. Z., additional, Mikkelsen, T., additional, Jhanwar, S., additional, Chin, L., additional, Nishihara, M., additional, Schliesser, M., additional, Grimm, C., additional, Weiss, E., additional, Claus, R., additional, Weichenhan, D., additional, Weiler, M., additional, Hielscher, T., additional, Sahm, F., additional, Wiestler, B., additional, Klein, A.-C., additional, Blaes, J., additional, Plass, C., additional, Wick, W., additional, Stragliotto, G., additional, Rahbar, A., additional, Soderberg-Naucler, C., additional, Won, M., additional, Ezhilarasan, R., additional, Sun, P., additional, Blumenthal, D., additional, Vogelbaum, M., additional, Jenkins, R., additional, Jeraj, R., additional, Brown, P., additional, Jaeckle, K., additional, Schiff, D., additional, Dignam, J., additional, Atkins, J., additional, Brachman, D., additional, Werner-Wasik, M., additional, Mehta, M., additional, Shen, J., additional, Luan, J., additional, Yu, A., additional, Matsutani, M., additional, Liang, Y., additional, Man, T.-K., additional, Trister, A., additional, Tokita, M., additional, Mikheeva, S., additional, Mikheev, A., additional, Friend, S., additional, van den Bent, M., additional, Erdem, L., additional, Gorlia, T., additional, Taphoorn, M., additional, Kros, J., additional, Wesseling, P., additional, Dubbink, H., additional, Ibdaih, A., additional, French, P., additional, van Thuijl, H., additional, Heimans, J., additional, Ylstra, B., additional, Reijneveld, J., additional, Prabowo, A., additional, Scheinin, I., additional, van Essen, H., additional, Spliet, W., additional, Ferrier, C., additional, van Rijen, P., additional, Veersema, T., additional, Thom, M., additional, Meeteren, A. S.-v., additional, Aronica, E., additional, Kim, H., additional, Zheng, S., additional, Brat, D. J., additional, Virk, S., additional, Amini, S., additional, Sougnez, C., additional, Barnholtz-Sloan, J., additional, Verhaak, R. G. W., additional, Watts, C., additional, Sottoriva, A., additional, Spiteri, I., additional, Piccirillo, S., additional, Touloumis, A., additional, Collins, P., additional, Marioni, J., additional, Curtis, C., additional, Tavare, S., additional, Tews, B., additional, Yeung, T. P. C., additional, Al-Khazraji, B., additional, Morrison, L., additional, Hoffman, L., additional, Jackson, D., additional, Lee, T.-Y., additional, Yartsev, S., additional, Bauman, G., additional, Fu, J., additional, Vegesna, R., additional, Mao, Y., additional, Heathcock, L. E., additional, Torres-Garcia, W., additional, Wang, S., additional, McKenna, A., additional, Brennan, C. W., additional, Yung, W. K. A., additional, Weinstein, J. N., additional, Sulman, E. P., additional, and Koul, D., additional

Published
2013
Full Text
View/download PDF

96. First ex vivo validation of a radioguided surgery technique with [formula omitted]-radiation.

Author

Solfaroli Camillocci, E., Schiariti, M., Bocci, V., Carollo, A., Chiodi, G., Colandrea, M., Collamati, F., Cremonesi, M., Donnarumma, R., Ferrari, M.E., Ferroli, P., Ghielmetti, F., Grana, C.M., Mancini Terracciano, C., Marafini, M., Morganti, S., Patanè, M., Pedroli, G., Pollo, B., and Recchia, L.

Abstract

Purpose A radio-guided surgery technique with β - -emitting radio-tracers was suggested to overcome the effect of the large penetration of γ radiation. The feasibility studies in the case of brain tumors and abdominal neuro-endocrine tumors were based on simulations starting from PET images with several underlying assumptions. This paper reports, as proof-of-principle of this technique, an ex vivo test on a meningioma patient. This test allowed to validate the whole chain, from the evaluation of the SUV of the tumor, to the assumptions on the bio-distribution and the signal detection. Methods A patient affected by meningioma was administered 300 MBq of 90 Y-DOTATOC. Several samples extracted from the meningioma and the nearby Dura Mater were analyzed with a β - probe designed specifically for this radio-guided surgery technique. The observed signals were compared both with the evaluation from the histology and with the Monte Carlo simulation. Results we obtained a large signal on the bulk tumor (105 cps) and a significant signal on residuals of ∼0.2 ml (28 cps). We also show that simulations predict correctly the observed yields and this allows us to estimate that the healthy tissues would return negligible signals (≈1 cps). This test also demonstrated that the exposure of the medical staff is negligible and that among the biological wastes only urine has a significant activity. Conclusions This proof-of-principle test on a patient assessed that the technique is feasible with negligible background to medical personnel and confirmed that the expectations obtained with Monte Carlo simulations starting from diagnostic PET images are correct. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

97. Identification of novel genomic markers related to progression to glioblastoma through genomic profiling of 25 primary glioma cell lines.

Author

Roversi, G., Pfundt, R., Moroni, R.F., Magnani, I., Reijmersdal, S.V. van, Pollo, B., Straatman, H.M.P.M., Larizza, L., Schoenmakers, E.F.P.M., Roversi, G., Pfundt, R., Moroni, R.F., Magnani, I., Reijmersdal, S.V. van, Pollo, B., Straatman, H.M.P.M., Larizza, L., and Schoenmakers, E.F.P.M.

Abstract

Contains fulltext : 51355reijmersdal.pdf (publisher's version ) (Closed access), Identification of genetic copy number changes in glial tumors is of importance in the context of improved/refined diagnostic, prognostic procedures and therapeutic decision-making. In order to detect recurrent genomic copy number changes that might play a role in glioma pathogenesis and/or progression, we characterized 25 primary glioma cell lines including 15 non glioblastoma (non GBM) (I-III WHO grade) and 10 GBM (IV WHO grade), by array comparative genomic hybridization, using a DNA microarray comprising approx. 3500 BACs covering the entire genome with a 1 Mb resolution and additional 800 BACs covering chromosome 19 at tiling path resolution. Combined evaluation by single clone and whole chromosome analysis plus 'moving average (MA) approach' enabled us to confirm most of the genetic abnormalities previously identified to be associated with glioma progression, including +1q32, +7, -10, -22q, PTEN and p16 loss, and to disclose new small genomic regions, some correlating with grade malignancy. Grade I-III gliomas exclusively showed losses at 3p26 (53%), 4q13-21 (33%) and 7p15-p21 (26%), whereas only GBMs exhibited 4p16.1 losses (40%). Other recurrent imbalances, such as losses at 4p15, 5q22-q23, 6p23-25, 12p13 and gains at 11p11-q13, were shared by different glioma grades. Three intervals with peak of loss could be further refined for chromosome 10 by our MA approach. Data analysis of full-coverage chromosome 19 highlighted two main regions of copy number gain, never described before in gliomas, at 19p13.11 and 19q13.13-13.2. The well-known 19q13.3 loss of heterozygosity area in gliomas was not frequently affected in our cell lines. Genomic hotspot detection facilitated the identification of small intervals resulting in positional candidate genes such as PRDM2 (1p36.21), LRP1B (2q22.3), ADARB2 (10p15.3), BCCIP (10q26.2) and ING1 (13q34) for losses and ECT2 (3q26.3), MDK, DDB2, IG20 (11p11.2) for gains. These data increase our current knowledge about cryptic geneti

Published
2006

98. hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines.

Author

Masi, A, Becchetti, A, Restano Cassulini, R, Polvani, S, Hofmann, G, Buccoliero, A, Paglierani, M, Pollo, B, Taddei, G, Gallina, P, Di Lorenzo, N, Franceschetti, S, Wanke, E, Arcangeli, A, Buccoliero, AM, Taddei, GL, Arcangeli, A., BECCHETTI, ANDREA, WANKE, ENZO, Masi, A, Becchetti, A, Restano Cassulini, R, Polvani, S, Hofmann, G, Buccoliero, A, Paglierani, M, Pollo, B, Taddei, G, Gallina, P, Di Lorenzo, N, Franceschetti, S, Wanke, E, Arcangeli, A, Buccoliero, AM, Taddei, GL, Arcangeli, A., BECCHETTI, ANDREA, and WANKE, ENZO

Abstract

Recent studies have led to considerable advancement in our understanding of the molecular mechanisms that underlie the relentless cell growth and invasiveness of human gliomas. Partial understanding of these mechanisms has (1) improved the classification for gliomas, by identifying prognostic subgroups, and (2) pointed to novel potential therapeutic targets. Some classes of ion channels have turned out to be involved in the pathogenesis and malignancy of gliomas. We studied the expression and properties of K+ channels in primary cultures obtained from surgical specimens: human ether a gò-gò related (hERG)1 voltage-dependent K+ channels, which have been found to be overexpressed in various human cancers, and human ether a gò-gò-like 2 channels, that share many of hERG1's biophysical features. The expression pattern of these two channels was compared to that of the classical inward rectifying K+ channels, IRK, that are widely expressed in astrocytic cells and classically considered a marker of astrocytic differentiation. In our study, hERG1 was found to be specifically overexpressed in high-grade astrocytomas, that is, glioblastoma multiforme (GBM). In addition, we present evidence that, in GBM cell lines, hERG1 channel activity actively contributes to malignancy by promoting vascular endothelial growth factor secretion, thus stimulating the neoangiogenesis typical of high-grade gliomas. Our data provide important confirmation for studies proposing the hERG1 channel as a molecular marker of tumour progression and a possible target for novel anticancer therapies. © 2005 Cancer Research.

Published
2005

99. LAB-OMICS AND PROGNOSTIC MARKERS

Author

Jensen, R. L., primary, Abraham, S., additional, Hu, N., additional, Jensen, R. L., additional, Boulay, J.-L., additional, Leu, S., additional, Frank, S., additional, Vassella, E., additional, Vajtai, I., additional, von Felten, S., additional, Taylor, E., additional, Schulz, M., additional, Hutter, G., additional, Sailer, M., additional, Hench, J., additional, Mariani, L., additional, van Thuijl, H. F., additional, Scheinin, I., additional, van Essen, D. F., additional, Heimans, J. J., additional, Wesseling, P., additional, Ylstra, B., additional, Reijneveld, J. C., additional, Borges, A. R., additional, Larrubia, P. L., additional, Marques, J. M. B., additional, Cerdan, S. G., additional, Brastianos, P., additional, Horowitz, P., additional, Santagata, S., additional, Jones, R. T., additional, McKenna, A., additional, Getz, G., additional, Ligon, K., additional, Palescandolo, E., additional, Van Hummelen, P., additional, Stemmer-Rachamimov, A., additional, Louis, D., additional, Hahn, W. C., additional, Dunn, I., additional, Beroukhim, R., additional, Guan, X., additional, Vengoechea, J., additional, Zheng, S., additional, Sloan, A., additional, Chen, Y., additional, Brat, D., additional, O'Neill, B. P., additional, Cohen, M., additional, Aldape, K., additional, Rosenfeld, S., additional, Noushmehr, H., additional, Verhaak, R. G., additional, Barnholtz-Sloan, J., additional, Bahassi, E. M., additional, Li, Y.-Q., additional, Cross, E., additional, Li, W., additional, Vijg, J., additional, McPherson, C., additional, Warnick, R., additional, Stambrook, P., additional, Rixe, O., additional, Manterola, L., additional, Tejada-Solis, S., additional, Diez-Valle, R., additional, Gonzalez, M., additional, Jauregui, P., additional, Sampron, N., additional, Barrena, C., additional, Ruiz, I., additional, Gallego, J., additional, Delattre, J.-Y., additional, de Munain, A. L., additional, Mlonso, M. M., additional, Saito, K., additional, Mukasa, A., additional, Nagae, G., additional, Aihara, K., additional, Takayanagi, S., additional, Aburatani, H., additional, Saito, N., additional, Kong, X.-T., additional, Fu, B. D., additional, Du, S., additional, Hasso, A. N., additional, Linskey, M. E., additional, Bota, D., additional, Li, C., additional, Chen, Y.-S., additional, Chen, Z.-p., additional, Kim, C. H., additional, Cheong, J. H., additional, Kim, J. M., additional, Yelon, N. P., additional, Jacoby, E., additional, Cohen, Z. R., additional, Ishida, J., additional, Kurozumi, K., additional, Ichikawa, T., additional, Onishi, M., additional, Fujii, K., additional, Shimazu, Y., additional, Date, I., additional, Narayanan, R., additional, Ho, Q. H., additional, Levin, B. S., additional, Maeder, M. L., additional, Joung, J. K., additional, Nutt, C. L., additional, Louis, D. N., additional, Thorsteinsdottir, J., additional, Fu, P., additional, Gehrmann, M., additional, Multhoff, G., additional, Tonn, J.-C., additional, Schichor, C., additional, Thirumoorthy, K., additional, Gordon, N., additional, Walston, S., additional, Patel, D., additional, Okamoto, M., additional, Chakravarti, A., additional, Palanichamy, K., additional, French, P., additional, Erdem, L., additional, Gravendeel, L., additional, de Rooi, J., additional, Eilers, P., additional, Idbaih, A., additional, Spliet, W., additional, den Dunnen, W., additional, Teepen, J., additional, Smitt, P. S., additional, Kros, J. M., additional, Gorlia, T., additional, van den Bent, M., additional, McCarthy, D., additional, Cook, R. W., additional, Oelschlager, K., additional, Maetzold, D., additional, Hanna, M., additional, Wick, W., additional, Meisner, C., additional, Hentschel, B., additional, Platten, M., additional, Sabel, M. C., additional, Koeppen, S., additional, Ketter, R., additional, Weiler, M., additional, Tabatabai, G., additional, Schilling, A., additional, von Deimling, A., additional, Gramatzki, D., additional, Westphal, M., additional, Schackert, G., additional, Loeffler, M., additional, Simon, M., additional, Reifenberger, G., additional, Weller, M., additional, Moren, L., additional, Johansson, M., additional, Bergenheim, T., additional, Antti, H., additional, Sulman, E. P., additional, Goodman, L. D., additional, Wani, K. M., additional, DeMonte, F., additional, Aldape, K. D., additional, Krischek, B., additional, Gugel, I., additional, Aref, D., additional, Marshall, C., additional, Croul, S., additional, Zadeh, G., additional, Nilsson, C. L., additional, Sulman, E., additional, Liu, H., additional, Wild, C., additional, Lichti, C. F., additional, Emmett, M. R., additional, Lang, F. F., additional, Conrad, C., additional, Alentorn, A., additional, Marie, Y., additional, Boisselier, B., additional, Carpetier, C., additional, Mokhtari, K., additional, Hoang-Xuan, K., additional, Capelle, L., additional, Lautenschlaeger, T., additional, Huebner, A., additional, McIntyre, J. B., additional, Magliocco, T., additional, Hamilton, M., additional, Easaw, J., additional, Pollo, B., additional, Calatozzolo, C., additional, Vuono, R., additional, Guzzetti, S., additional, Eoli, M., additional, Silvani, A., additional, Di Meco, F., additional, Filippini, G., additional, Finocchiaro, G., additional, Joy, A., additional, Ramesh, A., additional, Smirnov, I., additional, Reiser, M., additional, Shapiro, W., additional, Mills, G., additional, Kim, S., additional, Feuerstein, B., additional, Gonda, D. D., additional, Li, J., additional, McCabe, N., additional, Walker, S., additional, Goffard, N., additional, Wikstrom, K., additional, McLean, E., additional, Greenan, C., additional, Delaney, T., additional, McCarthy, M., additional, McDyer, F., additional, Keating, K. E., additional, James, I. F., additional, Harrison, T., additional, Mullan, P., additional, Harkin, D. P., additional, Carter, B. S., additional, Kennedy, R. D., additional, Chen, C. C., additional, Patel, A. S., additional, Allen, J. E., additional, Dicker, D. T., additional, Rizzo, K., additional, Sheehan, J. M., additional, Glantz, M. J., additional, El-Deiry, W. S., additional, Salhia, B., additional, Ross, J. T., additional, Kiefer, J., additional, Van Cott, C., additional, Metpally, R., additional, Baker, A., additional, Sibenaller, Z., additional, Nasser, S., additional, Ryken, T., additional, Ramanathan, R., additional, Berens, M. E., additional, Carpten, J., additional, Tran, N. L., additional, Bi, Y., additional, Pal, S., additional, Zhang, Z., additional, Gupta, R., additional, Macyszyn, L., additional, Fetting, H., additional, O'Rourke, D., additional, Davuluri, R. V., additional, Ezrin, A. M., additional, Moore, K., additional, Stummer, W., additional, Hadjipanayis, C. G., additional, Cahill, D. P., additional, Beiko, J., additional, Suki, D., additional, Prabhu, S., additional, Weinberg, J., additional, Lang, F., additional, Sawaya, R., additional, Rao, G., additional, McCutcheon, I., additional, Barker, F. G., additional, Trister, A. D., additional, Bot, B., additional, Fontes, K., additional, Bridge, C., additional, Baldock, A. L., additional, Rockhill, J. K., additional, Mrugala, M. M., additional, Rockne, R. R., additional, Huang, E., additional, Swanson, K. R., additional, Underhill, H. R., additional, Zhang, J., additional, Shi, M., additional, Lin, X., additional, Mikheev, A., additional, Rostomily, R. C., additional, Scheck, A. C., additional, Stafford, P., additional, Hughes, A., additional, Cichacz, Z., additional, Coons, S. W., additional, Johnston, S. A., additional, Mainwaring, L., additional, Craig, J., additional, Garcia, D., additional, Bergthold, G., additional, Burns, M., additional, Rich, B., additional, Ramkissoon, S., additional, Eberhart, C., additional, Ligon, A., additional, Goumnerova, L., additional, Stiles, C., additional, Kieran, M., additional, Hahn, W., additional, Olausson, K. H., additional, Correia, J., additional, Gafni, E., additional, Theisen, M., additional, Hayashi, M., additional, Haidar, S., additional, Maire, C., additional, Mainwaring, L. A., additional, Norden, A., additional, Wen, P., additional, Kung, A., additional, Alexander, B., additional, Tonellato, P., additional, and Ligon, K. L., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results